基于Th免疫应答、呼吸功能探讨多索茶碱联合辛伐他汀治疗COPD合并支气管哮喘的效果

Effect of doxofylline combined with simvastatin on the treatment of COPD complicated with bronchial asthma based on Th immune response and respiratory function

目的:探讨多索茶碱联合辛伐他汀治疗慢性阻塞性肺疾病(COPD)合并支气管哮喘的效果,分析其对Th免疫应答、呼吸功能、肺功能的影响。方法:选取2021年2月至2023年2月我院收治的97例COPD合并支气管哮喘患者为研究对象,随机分为对照组(48例)和研究组(49例),分别接受多索茶碱治疗和多索茶碱联合辛伐他汀治疗。统计对比2组临床疗效、不良反应发生情况及治疗前后肺功能、呼吸功能、哮喘相关临床指标[外周血嗜酸性粒细胞(EOS)计数、EOS比例、血清总免疫球蛋白E (IgE)]及Th1/Th2细胞因子[白细胞介素-2 (IL-2)、干扰素-γ (IFN-γ)、白细胞介素-4 (IL-4)、白细胞介素-6 (IL-6)]水平。结果:研究组总有效率高于对照组(P<0.05);治疗后,研究组肺功能、呼吸功能改善幅度大于对照组(P<0.05);治疗后,研究组EOS计数、EOS比例、IgE水平低于对照组(P<0.05);治疗后,研究组血清IL-2、IFN-γ水平高于对照组,血清IL-4、IL-6水平低于对照组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论:多索茶碱联合辛伐他汀治疗COPD合并支气管哮喘的疗效确切且具有一定安全性,可改善肺功能、呼吸功能,降低气道高敏反应性,可能与调节Th免疫应答有关。

Objective:To investigate the efficacy of doxofylline combined with simvastatin in the treatment of chronic obstructive pulmonary disease(COPD)complicated with bronchial asthma,and to analyze its effects on Th immune response,respiratory function and lung function.Methods:A total of 97 patients with COPD combined with bronchial asthma admitted to our hospital from Feb 2021 to Feb 2023 were selected as study subjects,and randomly divided into the control group(48 cases)and the study group(49 cases).The control group received doxofylline treatment and the study group received doxofylline combined with simvastatin treatment.The clinical efficacy,occurrence of adverse reactions,pulmonary function,respiratory function,asthma-related clinical indicators[peripheral blood eosinophils(EOS)count,EOS ratio,and serum total immunoglobulin E(IgE)],and Th1/Th2 cytokines[interleukin-2(IL-2),interferon-γ(IFN-γ),IL-4,and IL-6]levels before and after treatment were compared between the two groups.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).After treatment,the improvement of lung function and respiratory function in the study group was greater than that in the control group(P<0.05).EOS count,EOS ratio and IgE level in the study group were lower than those in the control group(P<0.05).The serum levels of IL-2 and IFN-γin the study group were higher than those in the control group(P<0.05),while the serum levels of IL-4 and IL-6 were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Doxofylline combined with simvastatin is effective and safe in the treatment of COPD complicated with bronchial asthma.It can improve lung function and respiratory function and reduce airway hypersensitivity,which may be related to the regulation of Th immune response.